Breakout Sessions : Considerations for Study Designs Incorporating RWD as Control Arm

jun 4, 2019: 2 p.m. - 3:30 p.m.
118A, Level 100

Ability to store, merge and analyze large volumes of data allows to introduce efficiencies into drug development. For example, one area of focus is to build external control arms. A number of companies and other stakeholders have been exploring how data from completed Clinical Trials or Real World Data (RWD) could augment or replace control arms in clinical trials of new drugs. Panelists will share their insights on methods for generating external control arms with data derived from either completed clinical trials or RWD, and start to establish best practices for incorporating these control into clinical trials.


Bill Louv

Bill Capra
Global Head of Real Wo...

Mark Stewart
Vice President, Scienc...

Jeremy Rassen
President & Chief Scie...

Somnath Sarkar
VP and the Head of Qua...

Pallavi Mishra-Kalyani
Lead Mathematical Stat...